M1 Kliniken AG (M12) AI Stock Analysis

• Market Cap: €261.49M
• Dividend Yield: 3.57%
• Average Volume (3M): 10.47K
• Price to Earnings (P/E): 14.7
• Beta (1Y): 0.39
• Revenue Growth: 6.52%
• EPS Growth: 7.17%
• Country: DE
• Employees: 219
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.63
• Shares Outstanding: 19,643,402
• 10 Day Avg. Volume: 8,258
• 30 Day Avg. Volume: 10,474
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €15.00
• Price Target Upside: 10.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 74 Outperform
• Price Target: €15.50 ▲(13.97% Upside)

M1 Kliniken AG's strong financial performance is the most significant factor, supported by solid revenue and cash flow growth. The technical analysis indicates a neutral market sentiment, while the valuation suggests the stock is fairly priced. The absence of earnings call data and corporate events does not impact the overall score.

M1 Kliniken AG Business Overview & Revenue Model

Company Description

M1 Kliniken AG, together with its subsidiaries, operates medical centers for aesthetic and plastic surgery in Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, and Australia. The company operates in two segments, Beauty and Trade. It develops and markets pharmaceutical, medical, and medical technology products for aesthetic medicine and cosmetic dermatology, as well as trades in pharmaceutical, biosimilars, and other medical products and devices in the areas of oncology, HIV, rheumatism, neurology, cardiovascular diseases, and narcotics. The company also engages in the acquisition, management, and sale of real estate, primarily in the health care sector. It offers its products to doctors, pharmacies, and wholesalers under the M1 Select brand. The company operates a network of outpatient specialist centers; and a specialized surgical clinic center, as well as 46 specialist centers under the M1 Med Beauty brand. M1 Kliniken AG was founded in 2007 and is based in Berlin, Germany. M1 Kliniken AG operates as a subsidiary of MPH Health Care AG.

How the Company Makes Money

M1 Kliniken AG generates revenue through its network of clinics that offer aesthetic medical treatments and procedures. The company's key revenue streams include the fees charged for cosmetic procedures such as Botox, dermal fillers, and plastic surgeries. Additionally, M1 Kliniken AG may earn money from the sale of related beauty products and partnerships with pharmaceutical and cosmetic companies. The company focuses on maintaining competitive pricing while ensuring high standards of medical care, which helps attract a broad customer base, contributing to its earnings.

M1 Kliniken AG Financial Statement Overview

Summary

M1 Kliniken AG exhibits strong financial performance with robust revenue growth, improved profit margins, and significant cash flow enhancement. The low leverage and solid equity position further bolster financial stability.

Income Statement

M1 Kliniken AG has demonstrated robust growth in its revenue over the past years, with the 2024 figures showing a 7.23% increase from 2023. The gross profit margin improved to 18.75%, indicating better cost management. The net profit margin also increased to 4.72%. Notably, the EBIT and EBITDA margins improved, reflecting enhanced operational efficiency. These factors contribute to a strong income statement performance.

Balance Sheet

The company's balance sheet reflects a solid equity base with a favorable equity ratio of 56.47%. The debt-to-equity ratio stands at 0.10, indicating low leverage and financial stability. The return on equity (ROE) has improved to 15.10%, showcasing effective utilization of equity. These strengths are slightly offset by a decrease in total assets and stockholders' equity.

Cash Flow

The cash flow statement shows significant improvement, with free cash flow growing by 334.57% from 2023 to 2024. The operating cash flow to net income ratio is strong at 1.91, indicating efficient cash conversion. The free cash flow to net income ratio is also favorable at 1.84. However, the company experienced negative investing cash flow, suggesting potential investment in future growth.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	339.18M	316.32M	285.29M	314.61M	159.59M
Gross Profit	63.60M	32.47M	21.72M	26.06M	13.61M
EBITDA	33.44M	21.79M	16.07M	19.78M	10.59M
Net Income	16.02M	10.27M	4.32M	8.91M	6.82M
Balance Sheet
Total Assets	187.87M	212.95M	197.02M	198.11M	188.74M
Cash, Cash Equivalents and Short-Term Investments	23.69M	22.76M	47.50M	49.12M	31.05M
Total Debt	10.42M	17.04M	19.67M	30.93M	39.32M
Total Liabilities	53.65M	69.73M	53.97M	58.21M	73.42M
Stockholders Equity	106.10M	113.25M	93.62M	95.03M	85.75M
Cash Flow
Free Cash Flow	29.55M	6.80M	19.25M	14.32M	7.93M
Operating Cash Flow	30.55M	7.81M	21.02M	15.66M	9.38M
Investing Cash Flow	-5.67M	-9.36M	-1.77M	-266.35K	2.94M
Financing Cash Flow	-30.44M	-14.81M	-21.97M	4.53M	712.76K

M1 Kliniken AG Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 13.60
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:M12, the sentiment is Neutral. The current price of 13.6 is below the 20-day moving average (MA) of 13.62, below the 50-day MA of 13.71, and below the 200-day MA of 14.33, indicating a neutral trend. The MACD of 0.08 indicates Negative momentum. The RSI at 51.35 is Neutral, neither overbought nor oversold. The STOCH value of 68.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:M12.

M1 Kliniken AG Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
M12	74 Outperform	€261.49M	14.73	15.61%	3.57%	6.52%	7.17%
MED	68 Neutral	140.60M	4.14	14.64%	1.35%	4.27%	―
93M1	66 Neutral	77.92M	-0.68	11.53%	6.59%	180.19%	-196.45%
LIK	64 Neutral	106.20M	22.58	16.98%	―	0.21%	7.53%
MAK	43 Neutral	23.07M	-1.75	19.68%	―	11.43%	7.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%